Leonard Braden Michael — SEC Form 4 filings
SEC reporting owner CIK 1373603. 39 Form 4 filings on record with FilingPulse; latest filed 2026-05-18.
Transaction summary — filings shown
Covers all 39 filings on record, filed 2024-03-19 to 2026-05-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 64 legs across 29 filings — 9,902,204 shares, $16,985,971 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 12 legs across 6 filings — 4,361,022 shares, $10,682,753 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 2,000,000 shares @ $1.16 ($2,320,000) in AN2 Therapeutics, Inc., filed 2025-05-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. (ADVM) | 10% owner | 11 | 20 legs · 1,252,536 sh · $6,188,611 | 4 legs · 1,099,446 sh · $4,608,205 | — |
| Aclaris Therapeutics, Inc. (ACRS) | 10% owner | 8 | 21 legs · 4,854,052 sh · $5,591,647 | 1 leg · 300,000 sh · $1,359,000 | — |
| AN2 Therapeutics, Inc. (ANTX) | 10% owner | 3 | 1 leg · 1,500,000 sh · $1,560,000 | 5 legs · 2,732,000 sh · $3,090,477 | — |
| OnKure Therapeutics, Inc. (OKUR) | — | 6 | 11 legs · 1,199,482 sh · $1,725,495 | — | 2 |
| ASTROTECH Corp (ASTC) | 10% owner | 1 | — | 2 legs · 229,576 sh · $1,625,071 | — |
| Tectonic Therapeutic, Inc. (TECX) | — | 2 | 3 legs · 766,635 sh · $971,493 | — | 2 |
| Cyteir Therapeutics, Inc. (CYT) | 10% owner | 2 | 2 legs · 284,366 sh · $845,706 | — | — |
| Talis Biomedical Corp (TLIS) | 10% owner | 4 | 6 legs · 45,133 sh · $103,019 | — | — |
| Outset Medical, Inc. (OM) | 10% owner | 2 | — | — | 3 |
Form 4 filings — Leonard Braden Michael
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-18 | 4 | Outset Medical, Inc. (OM) | Option exercise/expiry (X): 323,000 @ $5 | EDGAR |
| 2026-05-12 | 4 | Outset Medical, Inc. (OM) | Option exercise/expiry (X): 197,600 @ $5 · Option exercise/expiry (X): 96,900 @ $5 | EDGAR |
| 2026-04-27 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Sale (S): 300,000 @ $4.53 | EDGAR |
| 2025-12-05 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Sale (S): 524,560 @ $4.19 | EDGAR |
| 2025-12-03 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Sale (S): 300,000 @ $4.20 · Sale (S): 51,961 @ $4.20 · Sale (S): 222,925 @ $4.17 | EDGAR |
| 2025-10-07 | 4 | ASTROTECH Corp (ASTC) | Sale (S): 220,410 @ $7.13 · Sale (S): 9,166 @ $5.83 | EDGAR |
| 2025-06-16 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 200,000 @ $1.09 | EDGAR |
| 2025-05-30 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 2,000,000 @ $1.16 · Sale (S): 100,000 @ $1.16 · Sale (S): 425,000 @ $1.01 · Sale (S): 7,000 @ $1.03 | EDGAR |
| 2025-04-28 | 4/A | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-04-28 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-04-24 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 300,000 @ $3 · Purchase (P): 50,000 @ $2.98 | EDGAR |
| 2025-04-02 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 19,566 @ $4.38 · Purchase (P): 15,209 @ $4.04 | EDGAR |
| 2025-03-27 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 20,407 @ $5.04 · Purchase (P): 16,593 @ $5.19 | EDGAR |
| 2025-03-20 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 18,000 @ $4.60 · Purchase (P): 44,341 @ $4.73 · Purchase (P): 25,000 @ $4.94 · Purchase (P): 30,600 @ $5.61 | EDGAR |
| 2025-02-28 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 164,886 @ $4.01 · Purchase (P): 86,802 @ $4.46 · Purchase (P): 85,068 @ $4.60 | EDGAR |
| 2024-10-09 | 4 | OnKure Therapeutics, Inc. (OKUR) | Other (J): 345,739 · Other (J): 102,076 | EDGAR |
| 2024-09-26 | 4 | Reneo Pharmaceuticals, Inc. (RPHM) | Purchase (P): 29,600 @ $1.41 · Purchase (P): 68,746 @ $1.50 | EDGAR |
| 2024-09-19 | 4 | Reneo Pharmaceuticals, Inc. (RPHM) | Purchase (P): 55,300 @ $1.36 · Purchase (P): 806 @ $1.40 | EDGAR |
| 2024-09-16 | 4 | Reneo Pharmaceuticals, Inc. (RPHM) | Purchase (P): 36,176 @ $1.40 · Purchase (P): 150,000 @ $1.31 · Purchase (P): 172,747 @ $1.37 | EDGAR |
| 2024-09-09 | 4 | Talis Biomedical Corp (TLIS) | Purchase (P): 5,100 @ $1.40 · Purchase (P): 25,000 @ $1.48 | EDGAR |
| 2024-09-05 | 4 | Talis Biomedical Corp (TLIS) | Purchase (P): 500 @ $4 | EDGAR |
| 2024-09-04 | 4 | Talis Biomedical Corp (TLIS) | Purchase (P): 151 @ $4.25 | EDGAR |
| 2024-08-28 | 4 | Talis Biomedical Corp (TLIS) | Purchase (P): 13,167 @ $3.90 · Purchase (P): 1,215 @ $3.96 | EDGAR |
| 2024-08-14 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 1,500,000 @ $1.04 | EDGAR |
| 2024-08-14 | 4 | Reneo Pharmaceuticals, Inc. (RPHM) | Purchase (P): 171,339 @ $1.39 · Purchase (P): 100,487 @ $1.41 | EDGAR |
| 2024-08-05 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 167,544 @ $1.29 · Purchase (P): 206,025 @ $1.24 | EDGAR |
| 2024-07-31 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 173,730 @ $1.30 · Purchase (P): 100,000 @ $1.33 | EDGAR |
| 2024-07-31 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 85,800 @ $7.15 | EDGAR |
| 2024-07-22 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 130,317 @ $1.30 · Purchase (P): 6,689 @ $1.30 · Purchase (P): 17,716 @ $1.33 | EDGAR |
| 2024-07-18 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 135,546 @ $7.75 · Purchase (P): 80,718 @ $9.11 | EDGAR |
| 2024-07-05 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 86,092 @ $1.14 · Purchase (P): 143,288 @ $1.16 · Purchase (P): 123,017 @ $1.15 | EDGAR |
| 2024-07-01 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 235,000 @ $1.15 · Purchase (P): 801,000 @ $1.12 · Purchase (P): 400,000 @ $1.13 · Purchase (P): 107,434 @ $1.14 | EDGAR |
| 2024-06-25 | 4 | Tectonic Therapeutic, Inc. (TECX) | Other (J): 400,355 · Other (J): 33,333 | EDGAR |
| 2024-06-18 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 345,000 @ $1.17 · Purchase (P): 150,000 @ $1.13 · Purchase (P): 50,000 @ $1.13 | EDGAR |
| 2024-06-13 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Purchase (P): 1,000,000 @ $1.08 · Purchase (P): 82,579 @ $1.14 · Purchase (P): 28,621 @ $1.14 · Purchase (P): 500,000 @ $1.15 | EDGAR |
| 2024-05-16 | 4 | Reneo Pharmaceuticals, Inc. (RPHM) | Purchase (P): 79,281 @ $1.56 · Purchase (P): 335,000 @ $1.54 | EDGAR |
| 2024-05-15 | 4 | AVROBIO, Inc. (AVRO) | Purchase (P): 253,700 @ $1.24 · Purchase (P): 216,053 @ $1.26 · Purchase (P): 296,882 @ $1.30 | EDGAR |
| 2024-03-25 | 4 | Cyteir Therapeutics, Inc. (CYT) | Purchase (P): 170,589 @ $2.95 | EDGAR |
| 2024-03-19 | 4 | Cyteir Therapeutics, Inc. (CYT) | Purchase (P): 113,777 @ $3.01 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1373603 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →